Anti Neoplastic Agents Companies
Anti-neoplastic agents, also known as anticancer or chemotherapeutic agents, are medications used to treat various forms of cancer. These drugs work by targeting and inhibiting the growth of cancer cells.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Anti-Neoplastic Agents Companies Updates
Roche Holding AG (Switzerland) Secured an FDA breakthrough designation for its investigational bispecific T-cell engager, Tecentriq-Polatuzumab vedotin, for the treatment of triple-negative breast cancer (Jan 2024).
AstraZeneca PLC (UK) Announced positive Phase 3 data for its TROPIONâ„¢ (durvalumab) in combination with tremelimumab for the treatment of unresectable Stage III non-small cell lung cancer (Dec 2023).
Bristol-Myers Squibb Company (US) Received FDA approval for its Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) for the treatment of first-line advanced esophageal squamous cell carcinoma (Dec 2023).
Merck & Co., Inc. (US) Initiated Phase 3 trial for its investigational KRAS G12C inhibitor, AMG 598, for the treatment of non-small cell lung cancer (Jan 2024).BeiGene Ltd. (China): Entered into a strategic partnership with Novartis to co-develop and commercialize BeiGene's investigational anti-PD-1 antibody tislelizumab for global markets (Dec 2023).
List of Anti-Neoplastic Agents Key companies in the market:
- Amgen Inc.
- Boehringer Ingelheim GmbH
- Oxford BioTherapeutics Ltd.
- Bayer AG
- Aspen Holdings
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Baxter Healthcare Corporation
Â
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
